Probiotics: Strains, Evidence, Safety and How to Assess Claims

Probiotics are one of the fastest-growing supplement categories and one of the hardest to evaluate. Two products can both say "Lactobacillus" and behave completely differently, because what a probioticClinical does depends on the strain, not the genus or species. It is also the category where UK regulation is strictest: no health claims for probiotics are currently authorised in Great Britain.

Key points

• Probiotics are defined as live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.
• Effects are strain-specific. Evidence for one strain does not transfer to another.
• No health claims for probiotics are authorised for use in Great Britain, and the term "probioticClinical" itself is generally treated as an implied health claim on labels. Products are typically marketed as "live cultures".
• Evidence is strongest for defined strains in defined situations, notably antibiotic-associated diarrhoea and some symptoms of irritable bowel syndrome.
• People who are severely immunocompromised or critically ill should not take probiotics without medical advice.

What probiotics are

The gut microbiota comprises trillions of microorganisms, with composition varying substantially between individuals. Probiotics are live organisms taken with the aim of producing a benefit — distinct from prebiotics, which are non-digestible fibres that feed existing bacteria, and synbiotics, which combine both.

Common genera in supplements include Lactobacillus (and the reclassified genera derived from it, such as Lacticaseibacillus and Limosilactobacillus), Bifidobacterium, Streptococcus thermophilus, and the yeast Saccharomyces boulardii.

A proper strain designation looks like Lacticaseibacillus rhamnosus GG or Bifidobacterium animalis subsp. lactis BB-12 — genus, species and a strain code. If a label gives only "Lactobacillus acidophilus", you cannot connect it to any specific published research.

Why strain specificity matters

Different strains of the same species carry different genes and produce different metabolites, adhere differently to the gut lining, and interact differently with the immune system. A trial showing benefit for S. boulardii CNCM I-745 in antibiotic-associated diarrhoea tells you nothing about a different yeast or a Lactobacillus blend.

This is the single most useful thing to understand when reading probiotic marketing. Claims that cite "clinical studies" without naming the strain in the product are, in practice, unverifiable.

The regulatory position in Great Britain

Under retained EU law now operating as the GB nutrition and health claims regime, no health claims for probiotics have been authorised. Applications submitted over the years were not approved, generally on the grounds that the claimed effect was insufficiently characterised or the evidence insufficient.

In practice this means:

• The word "probiotic" on a label is generally regarded as an unauthorised implied health claim, which is why UK products commonly say "live cultures" or "friendly bacteria" instead.
• Statements such as "supports gut health", "improves digestion" or "supports immunity" attributed to live cultures are not permitted.
• Some products legitimately carry authorised claims for added vitamins — for example, a live culture product with added vitamin DClinical may state that vitamin DClinical contributes to normal immune function. The claim belongs to the vitamin, not the bacteria.

This regulatory position is about the standard of evidence required for a general population claim. It does not mean no probiotic has ever shown an effect in a trial.

What research says

Antibiotic-associated diarrhoea. This is the strongest area. Systematic reviews of specific strains, particularly S. boulardii and L. rhamnosus GG, report reduced incidence of antibiotic-associated diarrhoea, including in children. Effects vary by strain, dose and timing, and results are not uniform across trials.

Clostridioides difficile infection. Some meta-analyses suggest a reduction in risk with probiotics given alongside antibiotics in higher-risk settings, though large pragmatic trials in older hospitalised adults, notably PLACIDE, found no benefit. Guidance bodies have not adopted routine use.

Irritable bowel syndrome. NICE guidance on IBS states that people who choose to try probiotics should take them for at least four weeks at the manufacturer's recommended dose while monitoring the effect, and stop if there is no benefit. That is a pragmatic position, not an endorsement of a particular product.

Infant colic. Trials of Limosilactobacillus reuteri DSM 17938 in breastfed infants with colic have shown benefit in some studies and not others. Any use in infants should be discussed with a health visitor or GP.

Necrotising enterocolitis in preterm infants. This is an area with substantial trial evidence and specialist neonatal protocols. It is a hospital clinical decision, not a consumer one.

Immune function, mood, weight and skin. Research is active and often interesting, but the evidence base does not currently support general claims, and none are authorised in GB.

Fermented foods. Live yoghurt, kefir, sauerkraut, kimchi, miso and tempeh contain live organisms and are a reasonable, food-first way to include them. Note that pasteurisation after fermentation kills the cultures — jarred sauerkraut on an ambient shelf usually contains none.

Safety and who should be cautious

For generally healthy people, probiotics have a good safety record. Common effects are transient bloating, wind or changes in bowel habit in the first days.

Seek medical advice before use if you:

• Are severely immunocompromised — on chemotherapy, after transplant, with advanced HIV, or on high-dose immunosuppressants
• Are critically ill or in intensive care. Trials in severe acute pancreatitis found increased mortality with a particular multi-strain preparation
• Have a central venous catheter or damaged heart valves, given rare reports of bacteraemia and fungaemia
• Have short bowel syndrome or significant gut barrier compromise
• Are caring for a premature infant — use only under neonatal specialist direction
• Have a yeast allergy or sensitivity — relevant for S. boulardii products

Food supplements are not medicines and are not manufactured to pharmaceutical standards. Independent analyses have sometimes found discrepancies between labelled and actual viable counts.

How to assess a product responsibly

• Look for full strain identification — genus, species and strain code. If it is missing, the product cannot be linked to any specific evidence.
• Check CFU at end of shelf life, not "at time of manufacture". The second figure tells you little about what you will swallow.
• Match strain to purpose. If your reason is antibiotic-associated diarrhoea, look for strains studied in that context.
• Check storage requirements. Some strains need refrigeration; others are freeze-dried and shelf-stable. Follow the label.
• Give it a fair trial and then judge it. NICE's four-week suggestion for IBS is a sensible general approach — if nothing changes, stop.
• Be sceptical of high CFU counts as a selling point. More is not automatically better; the studied dose for the strain is what matters.
• Consider food first. Live yoghurt and kefir are inexpensive and part of a normal diet.
• Tell your GP or pharmacist what you are taking, particularly if you are unwell or immunocompromised.

Frequently asked questions

Do probiotics work?

Certain specific strains have shown benefit in specific situations, most consistently for antibiotic-associated diarrhoea. There is no evidence supporting general claims, and no probioticClinical health claims are authorised in Great Britain.

Why can't UK products say "probioticClinical" on the label?

Because the term is generally treated as an implied health claim, and no probiotic health claims have been authorised under the GB nutrition and health claims regime. Products therefore use terms like "live cultures".

Should I take probiotics with antibiotics?

Some strains have evidence in this context. If you want to try, choose a well-identified studied strain, take it a couple of hours apart from the antibiotic dose, and ask your pharmacist. Contact your GP if you develop severe or bloody diarrhoea.

How long should I take a probiotic before deciding?

NICE suggests that people with IBS who try probiotics take them for at least four weeks at the recommended dose, monitor the effect, and stop if there is no benefit.

Is yoghurt as good as a supplement?

Live yoghurt and kefir contain live cultures and are a sensible food-first option, though the strains and doses differ from studied supplement preparations.

Are probiotics safe for everyone?

Not for everyone. People who are severely immunocompromised, critically ill, have central lines, or are caring for premature infants should seek medical advice first.

Conclusion

Probiotics are a genuinely interesting field with a small number of well-evidenced, strain-specific uses and a very large amount of marketing built on top of it. The GB regulatory position — no authorised claims — reflects the gap between the two. Read for the strain code, check the CFU at end of shelf life, give a product a defined trial period, and speak to a healthcare professional if you are unwell or immunocompromised.